Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150068 | 0.90 | TSPO (0.39) | BCHENR1D1ALDH1A1MEN1KMT2A | |
| SCHEMBL28880216 | 0.87 | BCL2A1 (0.41) | BCL2A1HSP90AA1MEN1KMT2APTGDR2 | |
| SCHEMBL20151854 | 0.87 | NR1D1 (0.39) | BCL2A1BCHENR1D1ALDH1A1HSP90AA1 | |
| SCHEMBL20137411 | 0.87 | LTB4R2 (0.40) | BCHENR1D1 | |
| SCHEMBL20137099 | 0.84 | LMNA (0.41) | BCL2A1NR1D1ALDH1A1KMT2AACLY | |
| SCHEMBL20151842 | 0.79 | PPARD (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL20151838 | 0.78 | PPARG (0.39) | BCHEALDH1A1MEN1KMT2AACHE | |
| SCHEMBL20137037 | 0.76 | KDM4E (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL25802749 | 0.76 | TSPO (0.46) | BCL2A1BCHENR1D1ACHE | |
| SCHEMBL3506606 | 0.76 | SMN1; SMN2 (0.38) | BCL2A1BCHENR1D1ALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2022-01-19 | — | — | EP | disclosed |
| EP-3541822-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093946-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | BCL2A1 3623/4885BCHE 1310/4885NR1D1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.